Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label study of LentiGlobin BB305 in paediatric patients with beta thalassaemia major

Next Previous
Trial Profile

An open-label study of LentiGlobin BB305 in paediatric patients with beta thalassaemia major

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Betibeglogene-autotemcel (Primary)
  • Indications Beta-thalassaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Aug 2015 According to bluebird bio media release, NIH RAC review of HGB-207 (see 700257159) and HGB-208 study protocols in adult and adolescent patients with beta-thalassemia major and pediatric patients with beta-thalassemia major, respectively have been completed.
    • 21 May 2015 New trial record
    • 19 May 2015 bluebird bio plans to pursue conditional and accelerated registration strategies in EU and US, respectively. Company filed clinical study protocol for HGB-208 study with the NIH Recombinant DNA Advisory Committee (RAC) and was notified that HGB-208 study protocol is scheduled for public review on June 9, 2015. The data from this and three other studies (HGB-205, HGB-207 and HGB-208) will support the Biologics License Application (BLA) submission for LentiGlobin BB305.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top